BI IO Canada Inc.

Gary Glick’s fourth biotechnology firm, Scorpion Therapeutics , emerged from stealth mode on 26 October with $108m to develop small molecules that are safer, more tolerable and provide deeper, more d

In an interview with Scrip , Boehringer Ingelheim International GmbH ’s top business development executives offered their views on conducting transactions amid a pandemic, why a company usually focus

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker . Roche Pays Vividion $135m Up Front In

Germany’s family-owned multinational Boehringer Ingelheim International GmbH (BI) is acquiring preclinical antibody assets from two biotechs, Canada’s Northern Biologics Inc. and Switzerland’s CD